When should a patient with elevated ferritin be started on therapeutic phlebotomy?

When to Initiate Therapeutic Phlebotomy for Elevated Ferritin

Therapeutic phlebotomy should be started in patients with confirmed hereditary hemochromatosis (HFE-related) when serum ferritin is ≥300 µg/L in men or ≥200 µg/L in women, regardless of symptoms. 1, 2

Primary Indication: Hereditary Hemochromatosis

The decision to initiate phlebotomy depends on confirming iron overload rather than ferritin elevation alone, as 90% of elevated ferritin cases are due to non-iron overload conditions (inflammation, metabolic syndrome, liver disease, malignancy, infection) where phlebotomy is inappropriate. 3

Diagnostic Confirmation Required Before Treatment

• C282Y homozygotes with ferritin <1,000 µg/L and normal liver enzymes can proceed directly to phlebotomy without liver biopsy. 1
• MRI is the preferred method to confirm hepatic iron overload when the diagnosis is uncertain or ferritin is unexplained. 4
• Transferrin saturation >60% combined with ferritin >963 µg/L correctly identifies 95% of patients with severe hepatic iron overload (>7 mg/g dry weight). 5

Specific Ferritin Thresholds for Initiating Treatment

• Men: Begin phlebotomy at ferritin ≥300 µg/L 2
• Women: Begin phlebotomy at ferritin ≥200 µg/L 2
• Patients with end-organ damage (cirrhosis, diabetes, cardiomyopathy, arthropathy) should undergo phlebotomy regardless of ferritin level. 1

Treatment Protocol

Induction Phase

• Remove 500 mL blood weekly (or every 2 weeks) as tolerated, containing approximately 200-250 mg iron per unit. 6, 1
• Check hemoglobin/hematocrit before each session; do not allow decline >20% from baseline. 1, 4
• If hemoglobin falls to <12 g/dL, decrease phlebotomy frequency; if <11 g/dL, discontinue and reassess. 6
• Monitor ferritin every 10-12 phlebotomies (approximately every 3 months) initially. 1
• Continue weekly phlebotomy until ferritin reaches 50-100 µg/L. 6, 1

Target Ferritin Levels

• The therapeutic endpoint is ferritin 50-100 µg/L for both induction and maintenance phases. 6, 1, 4
• Avoid iron deficiency (ferritin <20 µg/L), as this increases dietary iron absorption and causes symptomatic deficiency. 6
• In elderly patients during maintenance, more relaxed targets (<200 µg/L in women, <300 µg/L in men) may be tolerated, though this is based on expert opinion rather than clinical studies. 6

Maintenance Phase

• After reaching target ferritin, maintenance phlebotomy frequency varies widely (monthly to 1-2 units yearly) based on individual iron reaccumulation rates. 1
• Monitor ferritin every 6 months during maintenance to keep levels within 50-100 µg/L range. 6
• Not all patients reaccumulate iron; some may not require maintenance phlebotomy. 1

When Phlebotomy is Contraindicated

Iron chelation therapy (deferoxamine 20-40 mg/kg/day subcutaneously or oral deferasirox) is indicated when patients cannot tolerate phlebotomy due to anemia, cardiac instability, or dyserythropoiesis. 1, 4

However, chelation removes only 10-20 mg iron daily compared to phlebotomy's 250 mg weekly, making it substantially less efficient. 1

Secondary Iron Overload in Cirrhosis

In cirrhotic patients with iron overload, therapeutic phlebotomy is first-line treatment when tolerated, using the same ferritin target of 50-100 µg/L. 4

• Iron overload occurs in 32-44% of cirrhotic patients and usually represents acquired hemosiderosis rather than hereditary hemochromatosis. 4
• Phlebotomy does not reverse established cirrhosis but may slow progression. 1, 4
• Patients with decompensated cirrhosis unable to undergo phlebotomy should be evaluated for liver transplantation. 4
• Adequate iron depletion before transplantation is critical; inadequate removal increases perioperative mortality from cardiac and infectious complications. 4

Critical Caveats

• Ferritin >1,000 µg/L with elevated transaminases or hepatomegaly warrants liver biopsy to assess fibrosis stage before initiating phlebotomy. 1, 4
• All cirrhotic patients require lifelong HCC surveillance with ultrasound every 6 months, even after successful iron depletion, as cirrhosis itself maintains cancer risk. 4
• HCC accounts for 30% of hemochromatosis-related deaths and is exceptionally rare in non-cirrhotic patients, providing strong rationale for early preventive therapy. 1
• Avoid vitamin C supplements during treatment, as they accelerate iron mobilization and increase oxidative stress. 1, 4
• Avoid raw shellfish due to heightened Vibrio vulnificus infection risk in iron-overloaded patients. 1, 4
• Dietary iron restriction provides minimal benefit (2-4 mg/day reduction) and is unnecessary. 1, 4

Response to Treatment

Phlebotomy improves fatigue, malaise, skin pigmentation, abdominal pain, and insulin requirements in diabetics, but does not reverse arthropathy, hypogonadism, or established cirrhosis. 1

Hepatic fibrosis may regress in approximately 30% of cases with adequate iron removal. 1